drugset / Trial / NCT06270225
A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment.
Timeline
- Start
- 2024-03-30
- Primary completion
- 2024-10
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Colchicine | Small molecule | 0.5 mg | — |
| Subject | SSGJ-613 | Monoclonal antibody | 100 mg | Subcutaneous |
| Subject | SSGJ-613 | Monoclonal antibody | 200 mg | Subcutaneous |